Paula K Schweitzer1, Russell Rosenberg2,3, Gary K Zammit4,5, Mark Gotfried6, Dan Chen7, Lawrence P Carter7,8, Hao Wang7, Yuan Lu7, Jed Black7,9, Atul Malhotra10, Kingman P Strohl11. 1. 1 Sleep Medicine and Research Center, St. Luke's Hospital, Chesterfield, Missouri. 2. 2 NeuroTrials Research, Atlanta, Georgia. 3. 3 Atlanta School of Sleep Medicine, Atlanta, Georgia. 4. 4 Clinilabs Drug Development Corporation, New York, New York. 5. 5 Icahn School of Medicine at Mount Sinai, New York, New York. 6. 6 Pulmonary Associates, PA, Phoenix, Arizona. 7. 7 Jazz Pharmaceuticals, Palo Alto, California. 8. 8 University of Arkansas for Medical Sciences, Little Rock, Arkansas. 9. 9 Stanford Center for Sleep Sciences and Medicine, Palo Alto, California. 10. 10 University of California, San Diego, San Diego, California; and. 11. 11 Case Western Reserve University, Cleveland, Ohio.
Abstract
Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence. Currently available pharmacologic options for the treatment of sleepiness in this population are limited. Objectives: To evaluate the efficacy and safety of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects, for the treatment of excessive sleepiness in participants with obstructive sleep apnea with current or prior sleep apnea treatment. Methods: This was a double-blind, randomized, placebo-controlled, parallel-group, 12-week trial comparing solriamfetol, 37.5, 75, 150, and 300 mg, with placebo. Measurements and Main Results: Of 476 randomized participants, 459 were included in the prespecified efficacy analyses. Coprimary endpoints (Maintenance of Wakefulness Test sleep latency and Epworth Sleepiness Scale score) were met at all solriamfetol doses (P < 0.05), with dose-dependent effects observed at Week 1 maintained over the study duration. All doses except 37.5 mg resulted in higher percentages of participants reporting improvement on Patient Global Impression of Change (key secondary endpoint; P < 0.05). Adverse events were reported in 47.9% of placebo- and 67.9% of solriamfetol-treated participants; five participants experienced serious adverse events (two [1.7%] placebo, three [0.8%] solriamfetol); none were deemed related to study drug. The most common adverse events with solriamfetol were headache (10.1%), nausea (7.9%), decreased appetite (7.6%), anxiety (7.0%), and nasopharyngitis (5.1%). Conclusions: Solriamfetol significantly increased wakefulness and reduced sleepiness in participants with obstructive sleep apnea and excessive sleepiness; most adverse events were mild or moderate in severity. Clinical trial registered with www.clinicaltrials.gov (NCT02348606) and www.eudract.ema.europa.eu (EudraCT 2014-005514-31).
RCT Entities:
Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence. Currently available pharmacologic options for the treatment of sleepiness in this population are limited. Objectives: To evaluate the efficacy and safety of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects, for the treatment of excessive sleepiness in participants with obstructive sleep apnea with current or prior sleep apnea treatment. Methods: This was a double-blind, randomized, placebo-controlled, parallel-group, 12-week trial comparing solriamfetol, 37.5, 75, 150, and 300 mg, with placebo. Measurements and Main Results: Of 476 randomized participants, 459 were included in the prespecified efficacy analyses. Coprimary endpoints (Maintenance of Wakefulness Test sleep latency and Epworth Sleepiness Scale score) were met at all solriamfetol doses (P < 0.05), with dose-dependent effects observed at Week 1 maintained over the study duration. All doses except 37.5 mg resulted in higher percentages of participants reporting improvement on Patient Global Impression of Change (key secondary endpoint; P < 0.05). Adverse events were reported in 47.9% of placebo- and 67.9% of solriamfetol-treated participants; five participants experienced serious adverse events (two [1.7%] placebo, three [0.8%] solriamfetol); none were deemed related to study drug. The most common adverse events with solriamfetol were headache (10.1%), nausea (7.9%), decreased appetite (7.6%), anxiety (7.0%), and nasopharyngitis (5.1%). Conclusions: Solriamfetol significantly increased wakefulness and reduced sleepiness in participants with obstructive sleep apnea and excessive sleepiness; most adverse events were mild or moderate in severity. Clinical trial registered with www.clinicaltrials.gov (NCT02348606) and www.eudract.ema.europa.eu (EudraCT 2014-005514-31).
Authors: E Shahar; C W Whitney; S Redline; E T Lee; A B Newman; F J Nieto; G T O'Connor; L L Boland; J E Schwartz; J M Samet Journal: Am J Respir Crit Care Med Date: 2001-01 Impact factor: 21.405
Authors: Kelly Posner; Gregory K Brown; Barbara Stanley; David A Brent; Kseniya V Yershova; Maria A Oquendo; Glenn W Currier; Glenn A Melvin; Laurence Greenhill; Sa Shen; J John Mann Journal: Am J Psychiatry Date: 2011-12 Impact factor: 18.112
Authors: I Koutsourelakis; E Perraki; N T Economou; P Dimitrokalli; E Vagiakis; C Roussos; S Zakynthinos Journal: Eur Respir J Date: 2009-04-08 Impact factor: 16.671
Authors: A E R Verbruggen; M Dieltjens; K Wouters; I De Volder; P H Van de Heyning; M J Braem; O M Vanderveken Journal: Sleep Med Date: 2013-12-30 Impact factor: 3.492
Authors: Merce Gasa; Renaud Tamisier; Sandrine H Launois; Marc Sapene; Francis Martin; Bruno Stach; Yves Grillet; Patrick Levy; Jean-Louis Pepin Journal: J Sleep Res Date: 2013-02-15 Impact factor: 3.981
Authors: Michelle G Baladi; Michael J Forster; Michael B Gatch; Richard B Mailman; Danielle L Hyman; Lawrence P Carter; Aaron Janowsky Journal: J Pharmacol Exp Ther Date: 2018-06-11 Impact factor: 4.030
Authors: Lucas M Donovan; Aditi Shah; Ching Li Chai-Coetzer; Ferran Barbé; Najib T Ayas; Vishesh K Kapur Journal: Chest Date: 2019-10-19 Impact factor: 9.410
Authors: Russell Rosenberg; Michael J Thorpy; Yves Dauvilliers; Paula K Schweitzer; Gary Zammit; Mark Gotfried; Shay Bujanover; Brian Scheckner; Atul Malhotra Journal: J Clin Sleep Med Date: 2022-01-01 Impact factor: 4.062
Authors: Terri E Weaver; Susan D Mathias; Ross D Crosby; Morgan Bron; Shay Bujanover; Diane Menno; Kathleen F Villa; Christopher Drake Journal: J Sleep Res Date: 2020-10-13 Impact factor: 3.981
Authors: Paula K Schweitzer; Kingman P Strohl; Geert Mayer; Russell Rosenberg; Patricia Chandler; Michelle Baladi; Lawrence Lee; Atul Malhotra Journal: J Clin Sleep Med Date: 2021-04-01 Impact factor: 4.062